Endpoints News – The biopharma world is here

SUBSCRIBE

top stories

Bicycle Therapeutics takes Roche's Genentech on an up to $2B immuno-oncology ride

10 hours ago

Biogen touts new evidence from the gene therapy company it wagered $800M on

9 hours ago

First US Covid-19 trials set to get underway in Nebraska and Washington, backed by NIH

10 hours ago

In final report, ICER appears to have a change of heart on new acute migraine therapies

9 hours ago

Latest

Most read

Sanofi outlines big API plans as coronavirus outbreak reportedly threatens shortage of 150 drugs

Yesterday

IDO-derived cancer vaccine scores in combo trial with Keytruda; Vir teams up with WuXi on coronavirus antibodies

9 hours ago

FDA launches searchable Purple Book

10 hours ago

When drug value assessment meets real-world evidence: ICER enlists Aetion in pricing evaluation

10 hours ago

Mallinckrodt, once the nation’s largest oxycodone producer, announces tentative $1.6B settlement

12 hours ago

UPDATED: NIH-partnered Moderna ships off its PhI-ready coronavirus vaccine candidate to a sea of uncertainty

12 hours ago

see latest stream

People

Gene therapy pioneer Kathy High has left Spark after completing $4.3B union with Roche

4 days ago

Fresh off $100M round, GV-backed real-world data startup woos Duke researcher as CMO

5 days ago

Merck loses its chief digital officer, spotlighting talent hunt for the hottest title in Big Pharma

5 days ago

Startups

Animal health vet Juergen Horn makes new antibody play for pets, raking $15M in Series A haul

Yesterday

Drug discovery in HD: Oxford spinoff's mass spectrometry approach scores fresh funding

Last week

Corey Goodman marshals $105M mega-round for his CD47 upstart, looking to break new ground in PhII

Last week

Deals

SoftBank's newest, $165M biotech investment looks for infectious traces in the blood

Yesterday

Harvard joins coronavirus fight with $115M and a high-profile Chinese partner

Yesterday

As coronavirus outbreak reaches 'tipping point,' GSK lends adjuvant tech to Chinese partner armed with preclinical ...

Yesterday

IPOs

As sickle cell patients find new options, NEA-founded Imara pitches mid-stage alternative for $86M IPO

Last week

The RAS rush: Revolution Medicines bags remarkable $238M IPO raise, more than doubling original goal

Last week

Party on: Base editing startup, computational drug discovery experts and CRO bag close to $2B total on their way to ...

3 weeks ago

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SUBSCRIBE NOW

Subscribe to Endpoints News

Premium storiesSee all

The top 100 biopharma venture investors at the megabillions deal table

Last week

The top 10 biopharma pipeline blowups, setbacks and snafus for H2 2019

3 weeks ago

Weak pipeline? Why, Sanofi execs are suddenly over the moon about their prospects

3 weeks ago

The power of precedent: How a one-off decision by Janet Woodcock established an unintended fast pathway at the FDA ...

4 weeks ago

Don't missSee all

UPDATED: Novartis' plans to wrestle Eylea market share take a hit as Beovu is linked to safety concerns

13 hours ago

UPDATED: NGM Bio takes leap forward in crowded NASH field

Yesterday

Novartis gets a boost in blockbuster multiple sclerosis race with Roche

Yesterday

The fourth CGRP migraine drug is here. Time for Lundbeck to prove it's worth $2B

3 days ago

Endpoints Standouts

Here are the 52 new drugs approved by the FDA in 2019. Who won? Who lost? And who just survived to 2020?

Last month

Special report: Twenty extraordinary women in biopharma R&D who worked their way to the top

3 months ago

Unlock the full Endpoints experience for your company — and support our mission of independent biopharma reporting

2 months ago

Publisher's note

[Video] Celebrating trial failures, changing the culture and allying with California dreamers: R&D chief Hal Barron ...

4 months ago

Peer review See all

Feb

21

Antonio Gualberto starts post-Kura career at Eisai subsidiary H3; eFFECTOR co-founder Siegfried Reich jumps to Turning Point

Feb

14

Palleon's first CSO explains how they (and she) got here; Enterprise taps Roche and Novartis vet David Morris as CMO

Feb

7

Craig Basson tells us why he leapt from NIBR to Boston Pharma; Ex-BMS Partner CytomX finds new CMO in Allison Hannah

Jan

31

Moderna woos trial vet Melanie Ivarsson to the senior R&D team; Ex-Roche CMO Sandra Horning joins Gilead board

Jan

24

Diabetes-focused Poxel names Eli Lilly vet David Moller as CSO; Acceleron's CBO hops ship to lead startup

R&D channel feed

4 days ago

A space odyssey for new antibiotics: MIT's machine learning approach

Drug development is complex, expensive and comes with lousy odds of success — but in most cases, if you make it across the finish line brandishing a product with an edge (and play your ...

READ MORE

Gilead loses two more patent challenges on HIV pill, setting up courtroom fight in Delaware

4 days ago

DBV's peanut prevention patch approaches key stage of approval process

4 days ago

latest in R&D

Armed with a batch of positive biomarker data, a rare disease player reaps $88M for the next big push in the clinic

5 days ago

For two decades, a new vaccine technology has been slowly approaching prime time. Now, can it stop a pandemic?

6 days ago

Cellectis boosts its coffers in revised off-the-shelf CAR-T deal with Servier

6 days ago

Bristol-Myers shrugs off another Opdivo combo flop as $1.74B deal goes pfffft

6 days ago

Astellas follows up $3B gene therapy buyout with $109M plan to accelerate a manufacturing boom

6 days ago

see latest stories

Pharma channel feed

4 days ago

Esperion's goldilocks cholesterol fighter wins FDA approval — will its 'traditional' pricing approach spur adoption?

It's better than decades-old statins, but not as effective as the injectable PCSK9 therapies — the goldilocks cholesterol therapy bempedoic acid has secured FDA approval. Its ...

READ MORE

Pharmacogenetics: FDA releases table of gene-drug interactions

4 days ago

Don't let AbbVie fool FTC with an easy divestiture, plead critics in latest attack on $63B Allergan buyout

5 days ago

latest in Pharma

Austedo, Teva's bright spot as it executes turnaround, fails two Tourette's trials

5 days ago

As bluebird makes commercial progress in Europe, US application for Zynteglo suffers delay

6 days ago

Former Novartis exec pleads guilty to generic price fixing

Last week

New entries, price hikes spur changes among the 20 most expensive drugs — though not the kind politicians like to see

Last week

Coronavirus outbreak clouds AstraZeneca's Q4 results and 2020 outlook

Last week

see latest stories